Furthermore, chemotherapy was found to potentially promote HGF/c-Met/IL-11 activation via SDC-1 shedding, exacerbating bone destruction in the setting of myeloma (Ramani et al., 2011). Here, SDC1 is linked to plasma cell myeloma.